The KIF1B Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the KIF1B gene has been disrupted in the HT29 human colorectal adenocarcinoma cell line. This polyclonal pool provides a heterogeneous loss-of-function model that avoids the need for single-cell clone isolation, enabling robust population-level analyses of gene disruption effects on tumor cell biology and intracellular trafficking.
HT29 cells are an established epithelial cell line derived from a colorectal adenocarcinoma, extensively used to investigate colorectal cancer pathogenesis, intestinal epithelial barrier function, and drug absorption. They retain key tumorigenic properties and the capacity to differentiate under specific conditions, making them a versatile host for studying cancer biology and pharmacological responses.
KIF1B encodes a kinesin-3 family motor protein that hydrolyzes ATP to transport cargo along microtubules, specifically mediating anterograde movement of mitochondria and synaptic vesicles. Functioning downstream of the tumor suppressor TP53 and subject to regulation by MYC, KIF1B interacts with BAX, PTPN21, KIFAP3, DYNLT1, and TRAK1. It facilitates mitochondrial trafficking and promotes BAX-mediated cytochrome c release, which activates APAF1 and caspase-9 to trigger apoptosis. Consequently, KIF1B functions as a critical node linking microtubule-dependent transport to apoptotic signaling and tumor suppression.
In HT29 colorectal adenocarcinoma cells, which harbor mutant TP53, KIF1B knockout provides a valuable system to dissect its tumor suppressor functions independently of wild-type p53. Disruption of KIF1B impairs mitochondrial distribution and may reduce apoptotic sensitivity, influencing cellular responses to chemotherapeutic agents. This model enables investigation of how mitochondrial trafficking defects affect drug-induced apoptosis and contribute to drug resistance in colorectal cancer.
Researchers can employ this knockout model to study KIF1B??s role in apoptosis through Annexin V assays, visualize mitochondrial morphology via immunofluorescence, and assess cell viability and drug sensitivity with MTT/ATP assays. Functional assays such as Transwell migration/invasion can evaluate metastatic potential, while co-immunoprecipitation or Western blotting can dissect protein interactions. Transcriptomic analysis by RNA-seq can reveal global gene expression changes. These polyclonal cells offer a robust platform for elucidating kinesin-mediated mechanisms in epithelial cancers and identifying therapeutic vulnerabilities. For technical support, please contact Ascent Research.
